Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.54, $0.33 better than the analyst estimate of $1.21. Revenue for the quarter came in at $515.2 million versus the consensus estimate of $518.2 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.